Sergey Jakimov at ARDD2025: 4 years into longevity investing: Takeaways deploying an early stage...

Value of the Information & Strength of the Argument

The talk provides valuable insights from a practitioner’s perspective, offering concrete data on deal flow, round sizes, and pharma partnerships. The argumentation is coherent and pragmatic, emphasizing the need for commercial viability in longevity biotech. However, the evidence is largely anecdotal and based on a single fund’s experience, limiting its generalizability. The speaker’s logic is sound, but the lack of external validation and potential conflicts of interest (as an investor promoting his own fund) should be considered.

Scientific Rigor, Source Quality, Title Accuracy

The talk is an expert opinion based on personal experience, not a scientific review. The speaker cites no external sources, but his claims are grounded in his fund’s data. The title accurately reflects the content. The presentation is well-structured and clear, but the lack of citations and reliance on anecdotal evidence reduce its scientific rigor.

The title accurately reflects the content: a presentation on lessons learned from four years of investing in longevity startups.

7/10

The speaker is a practitioner with direct experience in longevity investing, providing concrete data from their fund's operations. However, the talk is largely anecdotal and lacks peer-reviewed evidence or external validation. The claims are plausible but not independently verified.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction: importance of longevity biotech and need for success stories.
• 03:00Fund overview: LongeVC's portfolio, ecosystem, and team.
• 05:00Investment thesis: focus on age-related diseases and actionable targets.
• 07:00Deal flow funnel: from 2,500 companies to 20 investments.
• 09:00Round size trends: Series A rounds getting larger, bridge rounds shrinking.
• 11:00Pharma partnerships: 13 out of 20 portfolio companies have strategic deals.
• 13:00Examples: UNP and Turn Bio, importance of own pipeline.
• 15:00Common founder mistakes: overvaluing mouse studies, lack of regulatory focus.
• 17:00Current investor trends: focus on assets, NHP studies, pay-to-play terms.
• 19:00Conclusion: need for pragmatism and industry collaboration.